SCHEMBL16023964

SCHEMBL16023964

CCCCC/C=C\C/C=C\CCCCCCCCOc1cc(CO)cc(OCCCCCCCC/C=C\C/C=C\CCCCC)n1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 5/20 0.48
▸ CNR1 P21554 1/20 0.48
▸ CNR2 P34972 1/20 0.48
▸ F7 P08709 3/20 0.44
▸ F3 P13726 3/20 0.44
▸ PPARG P37231 2/20 0.44
▸ PPARD Q03181 2/20 0.44
▸ PPARA Q07869 2/20 0.44
▸ DUSP3 P51452 1/20 0.44
▸ PTPN7 P35236 1/20 0.44
▸ KDM4E B2RXH2 1/20 0.44
▸ FFAR1 O14842 1/20 0.44
▸ LMNA P02545 1/20 0.44
▸ FABP3 P05413 1/20 0.44
▸ CYP3A4 P08684 1/20 0.44
▸ CYP19A1 P11511 1/20 0.44
▸ FABP4 P15090 1/20 0.44
▸ HPGD P15428 1/20 0.44
▸ ALOX15 P16050 1/20 0.44
▸ TSHR P16473 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17685706 1.00 ALDH1A1 (0.48) ALDH1A1CNR1CNR2F7F3
SCHEMBL16154815 0.84 ALDH1A1 (0.40) ALDH1A1CNR1CNR2F7F3
SCHEMBL16013506 0.84 ALDH1A1 (0.40) ALDH1A1CNR1CNR2F7F3
SCHEMBL16013507 0.84 ALDH1A1 (0.40) ALDH1A1CNR1CNR2F7F3
SCHEMBL17685832 0.83 ALDH1A1 (0.50) ALDH1A1CNR1CNR2PPARA
SCHEMBL16154800 0.83 ALDH1A1 (0.50) ALDH1A1CNR1CNR2PPARA
SCHEMBL16154810 0.82 PLA2G2A (0.55) ALDH1A1F7F3PPARGPPARD
SCHEMBL17685721 0.82 PLA2G2A (0.55) ALDH1A1F7F3PPARGPPARD
SCHEMBL23656392 0.82 ALDH1A1 (0.38) ALDH1A1CNR1CNR2DUSP3PTPN7
SCHEMBL17685747 0.81 ALDH1A1 (0.40) ALDH1A1F7F3PPARGPPARD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3608308-B1 LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS NOVARTIS AG (CH) 2021-07-21 — — EP disclosed
EP-3608308-B1 LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS NOVARTIS AG (CH) 2021-07-21 — — EP disclosed
CN-107879960-B Lipids and lipid compositions for delivery of active ingredients 诺华股份有限公司 2021-06-22 — — CN disclosed
US-10792361-B2 Lipids and lipid compositions for the delivery of active agents NOVARTIS AG (CH) 2020-10-06 — — US disclosed
US-10792361-B2 Lipids and lipid compositions for the delivery of active agents NOVARTIS AG (CH) 2020-10-06 — — US disclosed
US-10729775-B2 Lipids and lipid compositions for the delivery of active agents NOVARTIS AG (CH) 2020-08-04 — — US disclosed
EP-3608308-A1 LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS Novartis AG (CH) 2020-02-12 — — EP disclosed
EP-2964608-B1 LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS NOVARTIS AG (CH) 2019-08-28 — — EP disclosed
EP-2964608-B1 LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS NOVARTIS AG (CH) 2019-08-28 — — EP disclosed
US-20180369386-A1 LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. 2018-12-27 — — US disclosed
US-20170196979-A1 LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS NOVARTIS AG (CH) 2017-07-13 — — US disclosed
US-20170196979-A1 LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS NOVARTIS AG (CH) 2017-07-13 — — US disclosed
US-9504747-B2 Lipids and lipid compositions for the delivery of active agents NOVARTIS AG (CH) 2016-11-29 — — US disclosed
US-9504747-B2 Lipids and lipid compositions for the delivery of active agents NOVARTIS AG (CH) 2016-11-29 — — US disclosed
US-20160106842-A1 LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. 2016-04-21 — — US disclosed
US-20160106842-A1 LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. 2016-04-21 — — US disclosed
US-20160106842-A1 LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. 2016-04-21 — — US disclosed
US-20140303232-A1 LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS NOVARTIS AG (CH) 2014-10-09 — — US disclosed
US-20140303232-A1 LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS NOVARTIS AG (CH) 2014-10-09 — — US disclosed
WO-2014136086-A1 LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS NOVARTIS AG (CH) 2014-09-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180369386-A1 LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS LIPA, LPAR1, LPAR4 ALDH1A1 2488/4885CNR1 1158/4885CNR2 2230/4885
US-20160106842-A1 LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS LIPA, LPAR1, LPAR4 ALDH1A1 2488/4885CNR1 1158/4885CNR2 2230/4885
US-10792361-B2 Lipids and lipid compositions for the delivery of active agents LIPA, LPAR1, LPAR4 ALDH1A1 2488/4885CNR1 1158/4885CNR2 2230/4885
US-20140303232-A1 LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS LIPA, LPAR1, LPAR4 ALDH1A1 2488/4885CNR1 1158/4885CNR2 2230/4885
US-10729775-B2 Lipids and lipid compositions for the delivery of active agents LIPA, LPAR1, LPAR4 ALDH1A1 2488/4885CNR1 1158/4885CNR2 2230/4885
US-20170196979-A1 LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS LIPA, LPAR1, LPAR4 ALDH1A1 2488/4885CNR1 1158/4885CNR2 2230/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback